Table 1. Patient characteristics and response by stage and level.

Pt. No.	Disease Stage	Prior Therapy	MMC	BCG	Bladder Status	Follow-up (mo)
1	HG Ta with LVI	None	10 mg in 20 ml	Half	NED	27.0
2	T1	None	10 mg in 20 ml	Half	NED	28.0
3	T1, nested variant	BCG	10 mg in 20 ml	Half	NED	24.8
4	HG Ta and T1	BCG × 2	10 mg in 20 ml	Full	NED	22.8
5	CIS	None	10 mg in 20 ml	Full	NED	22.6
6	CIS, HG Ta, and T1	None	10 mg in 20 ml	Full	NED	20.7
7	LG and HG Ta	BCG × 2	20 mg in 20 ml	Full	HG Ta	24.5
8	HG and LG Ta	BCG	20 mg in 20 ml	Full	NED	18.7
9	CIS and T1	XRT	20 mg in 20 ml	Full	NED	21.2
10	HG Ta	None	40 mg in 40 ml	Full	NED	18.2
11	T1, CIS	None	40 mg in 40 ml	Full	NED	19.3
12	T1, CIS	BCG × 2 and MMC	40 mg in 40 ml	Full	NED	8.4

BCG, bacillus Calmette-Guérin. CIS, carcinoma in-situ. HG, high grade. LG, low grade. LVI, lymphovascular invasion. MMC, Mitomycin C. NED, no evidence of disease. XRT, γ-irradiation therapy. Mo, months.